SEC Comment Letter for SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jul 26, 2018
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: July 26, 2018 · CIK: 0001390478 · Accession: 0000000000-18-022947
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226251
Letter
July 25, 2018 Angelos M. Stergiou, MD, ScD h.c. Chief Executive Officer SELLAS Life Sciences Group, Inc. 315 Madison Avenue, 4th Floor New York, NY 10017 Re:SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 Filed July 19, 2018 File No. 333-226251 Dear Mr. Stergiou: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Yvan-Claude Pierre, Esq.
Show Raw Text
July 25, 2018
Angelos M. Stergiou, MD, ScD h.c.
Chief Executive Officer
SELLAS Life Sciences Group, Inc.
315 Madison Avenue, 4th Floor
New York, NY 10017
Re:SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-3
Filed July 19, 2018
File No. 333-226251
Dear Mr. Stergiou:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Yvan-Claude Pierre, Esq.